NRG-HN005 / CHAN19131 / Oropharyngeal Radiation Therapy / Deepinder Singh
Research Question:
How well does a reduced dose of radiation therapy work with nivolumab compared to
cisplatin in treating patients with human papillomavirus (HPV)-positive oropharyngeal
cancer?
Basic Study Information
Purpose:
This phase II/III trial studies how well a reduced dose of radiation therapy works
with nivolumab compared to cisplatin in treating patients with human papillomavirus
(HPV)-positive oropharyngeal cancer that is early in its growth and may not have spread
to other parts of the body (early-stage), and is not associated with smoking. Radiation
therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Chemotherapy
drugs, such as cisplatin, work in different ways to stop the growth of tumor cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the
body's immune system attack the cancer, and may interfere with the ability of tumor
cells to grow and spread. This trial is being done to see if a reduced dose of radiation
therapy and nivolumab works as well as standard dose radiation therapy and cisplatin
in treating patients with oropharyngeal cancer.
Location: University of Rochester Medical Center
Study Reference #: CHAN19131
Lead Researcher (Principal Investigator)
Lead Researcher:
Deepinder Singh
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search